Oncolix, Inc. Announces Capital Raise of $4.2 Million
HOUSTON, TX, January 27, 2015 / — ONCOLIX, INC., announced today that it has completed a Series A round of financing, led by PoC Capital, LLC and Integrium Clinical Research, LLC. Also participating in the finance round was the Texas Emerging Technology Fund and certain healthcare-focused investors, representing gross proceeds to ONCOLIX of approximately $4.2 million. ONCOLIX plans to use the net proceeds from the offering to fund activities relating to its drug candidate, Prolanta™, for a Phase I dose-escalation clinical trial for the treatment of ovarian cancer.